[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
March 15, 2006

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients—Correction

JAMA. 2006;295(11):1252. doi:10.1001/jama.295.11.1252

Failure to Disclose Financial Interest: In the Original Contribution entitled “Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial” published in the February 15, 2006, issue of JAMA (2006;295:761-775), the following financial disclosure should be added for Julio Rosenstock, MD. On page 774, under “Financial Disclosures,” “Dr Rosenstock has received honoraria from Sanofi-Aventis for lectures and for consultant services” should be added right before “No other authors reported financial disclosures.”

×